Roth Capital Partners launched coverage of Genfit (PSE:GNFT) with a “buy” rating and 12-month price target of €116. The stock closed at €22.09 on Dec. 20.Read More
Ladenburg Thalmann initiated coverage of Molecular Templates (NASDAQ:MTEM) with a “buy” rating and $10.00 price target. The stock closed at $5.50 on August 2.Read More
Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor cancers.
The primary goal of the study was to assess safety and tolerability of SOR-C13 in subjects with advanced carcinomas commonly known to express the TRPV6 channel and who had failed all previous anti-cancer treatments. SOR-C13 is the first drug candidate targeting TRPV6 to enter human clinical trials.Read More